KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Bladder Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 55 (planned)
- Started
- Feb 9, 2026
- Main results expected
- Jul 8, 2031
- Fully finished
- Jul 8, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience an Adverse Event (AE)
Measured over: Up to approximately 27 months
Number of Participants Who Experience a Dose Limiting Toxicity (DLT)
Measured over: Up to approximately 21 days
Number of Participants Who Discontinue Study Treatment Due to an AE
Measured over: Up to approximately 24 months
Objective Response Rate (ORR) as Assessed by Investigator
Measured over: Up to approximately 58 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07232602 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC